Episode Details
Back to Episodes
Pharmaceutical Executive Daily: FDA Approves Tecentriq
Published 1 month, 1 week ago
Description
The FDA approves Roche’s Tecentriq for a subset of colon cancer patients, TRexBio and Retension Pharmaceuticals price new IPOs, and a Pharmaceutical Executive feature examines what it takes to turn precision medicine’s biological gains into deliverable therapies.